Innovent Biologics Partner Ollin Biosciences and Its Next-Gen Eye Disease Pipeline to Be Acquired

Stock News11-16 22:26

Innovent Biologics (01801) has announced that its partner Ollin Biosciences, Inc. (Ollin) has entered into an acquisition agreement with Johnson & Johnson (NYSE: JNJ).

Ollin's core pipeline asset OLN324 (Innovent's internal development code: IBI324) was developed and out-licensed by Innovent.

Founded in 2023, Ollin was established to discover and accelerate the development of next-generation ophthalmic therapies.

Its lead pipeline candidate OLN324 is a bispecific antibody targeting VEGF and Ang2 that is currently undergoing global Phase III clinical trials. Through molecular structure optimization and potency enhancement, it is intended for the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

These two severe retinal vascular diseases are among the leading causes of blindness worldwide, affecting more than 40 million patients globally.

Leveraging its differentiated molecular design and clinical data obtained to date, OLN324 is expected to achieve more effective resolution of retinal fluid and extend dosing intervals.

Recently, OLN324 has initiated patient enrollment for global Phase III clinical trials in both of the aforementioned indications.

Over the past few years, the company has worked closely with the Ollin team to jointly advance the clinical development of OLN324/IBI324.

Retinal vascular diseases affect tens of millions of patients worldwide. The shared goal of both parties is to develop this drug candidate into a novel therapeutic option with genuine clinical value.

The company is pleased to witness this important milestone for its partner, and the drug candidate holds the potential to achieve stronger and more durable disease control — a potential that has been recognized by a leading global pharmaceutical company.

The company will continue to work hand in hand with all partners to fully advance project development and bring benefits to patients with retinal vascular diseases worldwide as soon as possible.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment